Join the Gastric Cancer group to help and get support from people like you.
Gastric Cancer News
Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants
FRIDAY, June 21, 2024 – The cumulative risk for advanced gastric cancer varies from 6.5 to 10.3 percent for carriers of germline CDH1 pathogenic/likely pathogenic (P/LP) variants, according to a...
Gastrectomy for Gastric Cancer Tied to Lower Risk for Cardiovascular Events
TUESDAY, June 4, 2024 – Patients with gastric cancer who undergo gastrectomy have a lower risk for cardiovascular events than the general population, according to a study published online March 28...
Oral Rinse Might Alert Doctors to Stomach Cancers
FRIDAY, May 10, 2024 – A quick swish at the doctor’s office could someday provide early detection of stomach cancer, the fourth-leading cause of cancer deaths worldwide, a new study reports. R...
FDA Approves Hercessi (trastuzumab-strf), a Biosimilar to Herceptin
DURHAM, N.C., April 29, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
H. Pylori Testing Feasible for People in Community Settings
THURSDAY, April 18, 2024 – Community Helicobacter pylori (HP) testing in high-risk individuals is technically feasible, according to a study published online April 3 in Clinical Gastroenterology and ...
Today's Young Adults Are Aging Faster, and That Might Help Spur Cancers
MONDAY, April 8, 2024 – Younger generations are aging more rapidly, and this could be leading to an increased risk of cancer, a new study says. People born in or after 1965 are 17% more likely to be...
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 – For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free...
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
MONDAY, Feb. 12, 2024 – For patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who experienced disease progression on first-line chemotherapy, fruquintinib (F) plus...
Country Music Star Toby Keith Dies of Cancer at 62
TUESDAY, Feb. 6, 2024 – Country singer Toby Keith, best known for chart-topping hits like "Who’s Your Daddy?” and “Made in America," has died at 62 from stomach cancer. His death was announced on his...
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
FRIDAY, Dec. 22, 2023 – Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC), according to a study...
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
WEDNESDAY, Oct. 25, 2023 – For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and...
FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial ...
FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE) January 15, 2021 – Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has be...
FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti...